SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 12-15, 2026. ICU Medical’s presentation will be on Wednesday, January 14, 2026 at 1:30 p.m. PT (4:30 p.m. ET). Company management will also be participating in one-on-one meetings on We ...

Core Viewpoint - ICU Medical, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Group 1: Event Participation - Company management will take part in a fireside chat on December 4, 2025, at 10:00 a.m. PT (1:00 p.m. ET) [1]. - In addition to the fireside chat, management will engage in one-on-one meetings on the same day [1]. Group 2: Webcast Information - The fireside chat will be available for live streaming on the company's website, with a replay option also provided [2]. Group 3: Company Overview - ICU Medical is a global leader in infusion systems and critical care products, serving hospital, alternate site, and home care settings [3]. - The company is headquartered in San Clemente, California, and focuses on quality, innovation, and value for clinical customers worldwide [3].

Core Insights - Greenhaven Associates disclosed a new position in Baxter International, acquiring approximately 6,288,349 shares for about $143.19 million, representing 2.77% of its $5.17 billion in reportable equity holdings as of September 30, 2025 [2][3][8] Company Overview - Baxter International offers a diversified portfolio of healthcare products, including dialysis therapies, infusion systems, injectable drugs, anesthesia, surgical devices, and connected care technologies, serving healthcare providers in approximately 100 countries [4][5] - The company generates revenue primarily through the sale of medical devices, pharmaceuticals, and related services [4] Financial Performance - As of November 3, 2025, Baxter's stock was priced at $18.21, down 49.1% over the past year, significantly underperforming the S&P 500 by 67.93 percentage points [3] - Baxter's revenue for the trailing twelve months (TTM) is $11.02 billion, with a net income of -$341 million, and a dividend yield of 3.78% [3] Investment Context - Baxter's stock has declined by 78.14% over the last five years, while the S&P 500 index has gained 91.37% during the same period [7] - Greenhaven's investment may indicate growing confidence in a potential turnaround under new CEO Andrew Hider, who is focusing on strengthening the balance sheet and targeting a three-times net leverage by the end of 2026 [8] - The company is also reducing dividends to save over $300 million in annual cash flow, which could improve investor sentiment if successful [8] Market Valuation - Baxter is currently trading at 9.3 times forward earnings, which is considered reasonable in the current overheated market [9]

Core Insights - Baxter International Inc. is a global healthcare technology company with a market cap of $11.8 billion, specializing in essential hospital and renal-care products [1] - The company is expected to announce its fiscal third-quarter earnings on October 30, with analysts predicting a profit of $0.60 per share, a 25% decrease from the previous year's $0.80 per share [2] - Analysts forecast an EPS of $2.45 for the current year, representing a 29.6% increase from $1.89 in fiscal 2024, and a further rise to $2.60 in FY2026 [3] Stock Performance - BAX stock has declined by 37.3% over the past year, underperforming the S&P 500 Index's 16.9% gain and the Health Care Select Sector SPDR Fund's 2.3% dip [4] - Recent pressures on BAX shares include a 3% drop on October 10 due to market-wide sell-offs linked to trade tensions with China [5] - A 3.7% decline occurred on September 25 following a U.S. Commerce Department investigation into medical equipment imports, raising concerns about potential tariffs and supply chain disruptions [6] Analyst Ratings - The consensus opinion on BAX stock is neutral, with an overall "Hold" rating from 16 analysts: three recommend "Strong Buy," twelve suggest "Hold," and one advises "Moderate Sell" [7] - The average analyst price target for BAX is $27.71, indicating a potential upside of 20.4% from current levels [7]

Core Points - ICU Medical, Inc. will release its third quarter 2025 earnings results on November 6, 2025, at approximately 4:00 p.m. ET [2] - A conference call to discuss the results will take place on the same day at 4:30 p.m. ET, accessible via phone and webcast [2] - ICU Medical is a global leader in infusion systems and critical care products, focusing on quality and innovation for clinical customers [3]

Core Viewpoint - ICU Medical, Inc. is set to release its second quarter 2025 earnings results on August 7, 2025, followed by a conference call to discuss these results [1][2]. Company Information - ICU Medical is a global leader in infusion systems, infusion consumables, and high-value critical care products used in various healthcare settings [3]. - The company is headquartered in San Clemente, California, and focuses on providing quality, innovation, and value to clinical customers worldwide [3].